B. J. O'Connor (London, United Kingdom), A. Papi (Ferrara, Italy)
Measuring asthma control: a comparison of three classification systems
P. M. O‘Byrne, H. K. Reddel, S. Peterson, O. Ostlund, G. Eriksson, E. D. Bateman (Hamilton, Canada; Sydney, Australia; Lund, Sweden)
|  |
Mast cell mediator release during refractoriness to mannitol-induced bronchoconstriction
J. Larsson, C. Perry, J. Brannan, S. Anderson, S. E. Dahlén, B. Dahlén (Stockholm, Sweden; Sydney, Australia)
| |
Barriers to the continued use of omalizumab in a small outpatient setting
A. Redford, M. L. Zaremba, S. Ali, N. Shah, S. Reddy (Port Huron, United States Of America)
| |
High doses inhaled salbutamol by MDI in patients with acute bronchial asthma and its cardiopulmonary effects
J. K. Samaria (Varanasi, India)
| |
Inhaled corticosteroids only decrease on the lymphocytes PGP expression and antileukotrienes mrp expression in asthmatic children after one month treatment
J. Potesil, F. Kopriva, P. Dzubak, M. Hajduch (Olomouc, Czech Republic)
| |
The medicamentous factors influencing on levels of control BA in Kyrgyzstan
A. Altymysheva, S. Shabykeeva, S. Abilova, T. Sooronbaev (Bishkek, Kyrgyzstan)
| |
Twice-daily fluticasone propionate (fp)/formoterol fumarate (fm) HFA PMDI combination therapy is safe, efficacious and reduces asthma exacerbations in patients with mild to moderate asthma
Y. Feshchenko, N. Primushko, N. Parkomenko, K. Kaiser (Kyiv, Ukraine; Muttenz, Switzerland)
| |
Bronchoprotective and anti-inflammatory effect of beclometasone dipropionate plus formoterol HFA fixed combination in asthmatic patients
B. J. O‘Connor, S. Collarini, G. Poli, C. Brindicci, D. Acerbi, P. J. Barnes, B. Leaker (Parma, Italy; London, United Kingdom)
| |
Effect on small airway obstruction of two different long-term LABA+ics treatments in asthmatic patients
G. Gardini, L. Corda, M. Guerini, G. E. La Piana, L. Taranto Montemurro, C. Tantucci (Brescia, Italy)
|  |
Characterisation of asthma flare ups
M. White, H. Nolte (Wheaton, Kenilworth, United States Of America)
| |
Asthma control test score with respect to regularity of medication use among adult asthma patients in central European countries
M. Turel, A. Bekere, K. Malakauskas, Z. Bartfai, M. Hrubisko, M. Pohar Perme, A. Ostir (Ljubljana, Slovenia; Riga, Latvia; Kaunas, Lithuania; Budapest, Hungary; Bratislava, Slovakia)
| |
Treatment modification with respect to asthma control test score among adult asthma patients in central European countries
M. Turel, A. Bekere, K. Malakauskas, Z. Bartfai, M. Hrubisko, M. Pohar Perme, A. Ostir (Ljubljana, Slovenia; Riga, Latvia; Kaunas, Lithuania; Budapest, Hungary; Bratislava, Slovakia)
| |
Agreement between doctor and patient evaluation of asthma with respect to asthma control test score in central European countries
M. Turel, A. Bekere, K. Malakauskas, Z. Bartfai, M. Hrubisko, M. Pohar Perme, A. Ostir (Ljubljana, Slovenia; Riga, Latvia; Kaunas, Lithuania; Budapest, Hungary; Bratislava, Slovakia)
| |
Comparison of salmeterol/fluticasone propionate (sal/fp) combination versus monotherapy with fluticasone propionate (fp) in patients with mild to moderate asthma
N. Syed, J. Joshi, P. Niphadkar, C. J. Po, M. Mangale, S. Chachad, S. Purandare, A. Sule, A. Lulla (Mumbai, India)
| |
Involvement of angiotensins on bronchomotor effects of adenosine
B. Gurzu, I. L. Dumitriu, E. Cojocaru, M. Costuleanu, S. M. Slatineanu, G. Petrescu (Iasi, Romania)
| |
Comparitive study for evaluation of efficacy and safety of doxofylline and theophylline in chronic persistent asthma
R. K. Jenaw, S. Jindal, N. K. Jain, K. K. Sharma, M. Gupta (Jaipur, India)
| |
Omalizumab for the treatment of asthma: subspeciality in the district
J. Miles, K. Ballance, H. Ford (Manchester, United Kingdom)
| |
Treatment of patients with uncontrolled asthma using high dose inhaled corticosteroids administered by controlled inhalation – a retrospective analysis
H. Jung, T. Rothe, G. Menz (Davos Wolfgang, Switzerland)
| |
Does azithromycin-prednisolone combination therapy have additive effects than single therapy in patients with persistent asthma?
M. Ghanei, M. Hosseini, A. Ani, M. A. Abbasi, J. Aslani (Tehran, Islamic Republic Of Iran)
| |
Impact of omalizumab in patients with severe asthma
N. Pires, A. Amorim, I. Gomes, I. Araújo (Porto, Portugal)
| |